Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of tumour response to treatment and in 2 patients complete remissions were observed. However in most patients, responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months from first recorded evidence of distant metastatic disease.
 ...
PMID:Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. 635 83

A review of the current status of chemotherapy in the treatment of retinoblastoma is presented. No consistently effective chemotherapeutic regimen for intraocular tumor has yet been discovered. An adjunctive role in the treatment of extraocular orbital disease has been suggested, but is unproven. Central nervous system involvement often responds to intrathecal chemotherapy. In cases diagnosed early, cure may be possible by the use of aggressive regimens including radiation therapy. Complete remissions are generally achieved in patients with systemic metastases. Cyclophosphamide is the most effective of the drugs used so far. However, relapses invariably follow, because effective maintenance chemotherapy has not yet been developed. Prevention of overt metastases by the use of adjuvant chemotherapy has recently been studied, but results remain inconclusive. Identification of reproducible prognostic criteria will enhance the design of future clinical studies. Laboratory research shows promise of more effective chemotherapeutic agents and combinations.
 ...
PMID:The role of chemotherapy in the treatment of retinoblastoma. 635 60

Resistance of mouse M5076 (M5) ovarian reticular cell sarcoma to cyclophosphamide (CTX) was obtained in vivo by repeated drug treatment followed by transplantation of the regrowing tumor. After 16 passages, we obtained an M5 subline resistant to CTX (M5-CTX-16R). Median survival times were approximately 29 and 39 days for M5 and M5-CTX-16R, respectively. Survival of M5-bearing mice given a single i.p. dose of 200 or 300 mg/kg was 160 and 168% of controls, respectively, whereas in M5-CTX-16R it ws 103 and 123%, respectively. The resistance was not reversible after 14 additional passages with no further CTX treatment. M5 and M5-CTX-16R appear similar in histological features, pattern of metastasis formation, and DNA content, as assessed by flow cytometry (hypotetraploid). Metastases of M5-CTX-16R were also resistant to CTX. Flow cytometry studies 12 and 24 hr after CTX treatment revealed a block in S and G2-M phases in both tumors. After 48 hr and at subsequent times, no cytokinetic pertubation was evident in M5-CTX-16R, whereas in M5 marked accumulation of cells in G2-M was observed at 48, 72, 96, and 120 hr. Cross-resistance was found between CTX, L-phenylalanine mustard, chlorambucil, and hexamethylmelamine. M5-CTX-16R was sensitive, but less so than M5, to cis-platinum, 1,3-bis(2-chloroethyl)-1-nitrosourea, and imidazole-4-carboxamide,5-(3,3-dimethyl-1-triazene). Adriamycin was equally active on M5 and M5-CTX-16R, while 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidine-beta-D-glucopyranoside) was inactive. This model appears to be suitable for studies on the mechanism of resistance to CTX and alkylating agents and for screening new, non-cross-resistant drugs.
 ...
PMID:Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. 635 29

Inoperable non- microcellular primary bronchial carcinomas have been reputed up to now to be chemo-resistant. The introduction of Cis-platinum into a polychemotherapy protocol leads to revision of this concept. The authors report the preliminary results of a polychemotherapy protocol (including Cis-platinum, Vindesine, CCNU, Cyclophosphamide) associated, in cases of non- metastasized carcinomas, with radiotherapy to the tumour itself, the mediastinum and the supraclavicular fossae. These results confirmed the value of such chemotherapy in forms with metastases. In localised inoperable forms, conclusions could be reached only on the basis of a randomised comparative trial of chemotherapy + radiotherapy versus radiotherapy alone.
 ...
PMID:[Preliminary results concerning the value of chemotherapy in the treatment of inoperable bronchial carcinoma (excluding small-cell anaplastic carcinoma)]. 637 40

A recently developed metastatic tumor model was used to study the therapeutic response of liver metastases derived from intrasplenically growing LLT. Treatment was performed on the day following surgical removal of the 'primary tumor'. The life-span of tumor-bearing animals and the number and volume of liver metastases were measured. Cyclophosphamide and 13324 (a new bifunctional nitrosoureido derivative) proved to be most effective. Some other drugs (5-FU, MeCCNU, Lycurim) showed a temporary regression in the formation of macrometastases without influencing the life-span. Adriamycin was slightly more effective given i.p. than i.v.
Clin Exp Metastasis
PMID:Chemotherapeutic sensitivity of liver metastases from intrasplenically-growing Lewis lung tumor. 644 44

Cyclophosphamide (CY) administration prior to intravenous tumor cells injection resulted in a rapid increase of the number of neoplastic nodules in the lungs. It was tested whether the elimination of the possible suppressive effect of CY on the immunological system by reconstitution of the animals with the spleen lymphocytes would diminish CY effect and reduce the number of tumor nodules in the lungs. This procedure only partially eliminates the effect of the growing number of artificial metastases.
 ...
PMID:The effect of cyclophosphamide on artificial metastases formation in the lungs of Balb/c mice. 652 28

The pattern of lung colonization of L929-MM4 metastasis-derived cells was studied in C3HA/Hab mice. The incidence of mice with lung tumors and the number of tumor foci increased with the number of tumor cells in the i.v. inoculum until a 'plateau' was reached. However, some 30 per cent of the animals continued to show no macroscopic or microscopic evidence of metastases. Twenty days after the i.v. injection of 2.5 X 10(5) L929-MM4 cells, viable tumor cells were recovered from 80-90 per cent of the animals as judged by in vivo or in vitro assay methods, even though survival of mice under these conditions was 50 per cent at the end of a 3-month period. These results are discussed in relation to possible tumor dormant states. Cyclophosphamide stimulated both the incidence and the number of lung tumor foci after i.v. injection of tumor cells, if the drug was administered before the tumor cell inoculum. On the basis of the observed time dependency of this effect, and the low immunogenicity of L929-MM4 cells in C3HA/Hab mice, the results could be explained on the basis of drug damage to normal cells.
Clin Exp Metastasis
PMID:Pattern of organ colonization of metastasizing mouse L929-MM4 cells and the stimulation of lung tumor formation by cyclophosphamide. 654 2

A metastasizing tumour model in which a non-immunogenic tumor (Lewis lung carcinoma) is implanted in the caecum of syngeneic mice, is described. The most interesting property of this model is the formation of spontaneous hepatic and transperitoneal metastases. Resection of the caecum tumor 14 days after implantation leaves micrometastases in liver, peritoneum and lungs. This gives the opportunity for the study of adjuvant therapy. Adjuvant chemotherapy with cyclophosphamide cured a significant percentage of animals with micrometastases in liver and peritoneum. Cyclophosphamide therapy had no effect on micrometastases in liver and peritoneum when the primary tumor was left in place. This finding underlines the importance of aggressive treatment of the primary tumor before adjuvant chemotherapy can be effective in colorectal cancer.
Clin Exp Metastasis
PMID:Adjuvant chemotherapy in a new metastasizing caecum tumor model. 654 8

Two cases of Burkitt's tumor treated in the Pediatric Hospital, Owendo, Libreville are discussed. The tumors were of the maxillofacial type, and remission by chemotherapy was obtained for a period of between 6 to 8 months. After this length of time, and in spite of spectacular local results, metastases developed and led to a fatal outcome. Cyclophosphamide chemotherapy is effective locally, but does not prevent recurrence.
 ...
PMID:[Malignant lymphoma or Burkitt's tumor. Apropos of 2 cases]. 685 Sep 51

The purpose of this study was to detect possible factors related to the occurrence of DIC in carcinoma patients. I) We studied 20 carcinoma cases accompanied with DIC. Results; The carcinomas most frequently accompanied with DIC were cancers of the biliary system, gastric, hepatic and pancreatic cancer, especially those with distant metastases. Pneumonia, UTI and biliary tract infections seemed to be the most important triggers of DIC. No significant relationship was found between anti-cancer chemotherapy and the DIC incidence. Endotoxemia was more frequently detected in patients having received anti-cancer drugs than in those who not. II) The effects of anti-cancer chemotherapy on the incidence of endotoxemia was examined in rats. A higher incidence of endotoxemia was noted in the groups treated with high doses of 5-FU or Cyclophosphamide. The incidence of endotoxemia seemed to run parallel with the incidence of diarrhea and of weight loss in each animal group.
 ...
PMID:[Clinical and experimental studies on DIC found in carcinoma; correlation between anti-cancer drug administration and endotoxemia]. 687 46


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>